Carbogen Amcis Manchester won the industry award in recognition of its efficiency improvement program implemented in response to increased demand for its products
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Appoints Dr Rafiq Hasan as CEO
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)